{"id":"NCT05073315","sponsor":"Amgen","briefTitle":"A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis","officialTitle":"A Multicenter, Randomized, Double-blind Study Evaluating the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Multiple Switches Between Humira® (Adalimumab [US]) and ABP 501 Compared With Continued Use of Adalimumab in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-10-04","primaryCompletion":"2022-12-19","completion":"2022-12-19","firstPosted":"2021-10-11","resultsPosted":"2024-02-09","lastUpdate":"2024-02-09"},"enrollment":425,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"Adalimumab","otherNames":["Humira®"]},{"type":"DRUG","name":"ABP 501","otherNames":[]}],"arms":[{"label":"Continued-use Group (Adalimumab)","type":"ACTIVE_COMPARATOR"},{"label":"Switching Group (Adalimumab - ABP 501)","type":"EXPERIMENTAL"}],"summary":"Study to evaluate pharmacokinetics, efficacy, safety and immunogenicity of multiple switches between Humira® and ABP 501 (new high concentration formulation) compared with continued use of Humira® in participants with moderate to severe plaque psoriasis. This multi-center study is composed of two periods: A lead-in period of treatment with Humira® followed by a randomized two parallel arm period.","primaryOutcome":{"measure":"Area Under the Curve From Time 0 Over the Dosing Interval (AUCtau) of ABP 501 (Switching Group) and Adalimumab (Continued-use Group)","timeFrame":"Week 28 pre-dose and 1hour, 1 day, 3 days, 4 days, 7 days, 11 days, and 14 days post Week 28 dose","effectByArm":[{"arm":"Period 2 (Switching Group)","deltaMin":1458.03,"sd":156.6},{"arm":"Period 2 (Continued-use Group)","deltaMin":1472.68,"sd":174.9}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":88,"countries":["United States","Canada","Estonia","Germany","Latvia","Poland"]},"refs":{"pmids":[],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":425},"commonTop":["Nasopharyngitis","COVID-19","Headache"]}}